• 1.

    Furuta S, Jayne DRW. Antineutrophil cytoplasm antibody-associated vasculitis: Recent developments. Kidney Int 2013; 84:244249. doi: 10.1038/ki.2013.24

  • 2.

    Halbwachs L, Lesavre P. Endothelium-neutrophil interactions in ANCA-associated diseases. J Am Soc Nephrol 2012; 23:14491461. doi: 10.1681/ASN.2012020119

  • 3.

    Jayne DRW, et al.. Randomized trial of C5a receptor inhibitor avacopan in ANCA-associated vasculitis. J Am Soc Nephrol 2017; 28:27562767. doi: 10.1681/ASN.2016111179

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Jayne DRW, et al.. Avacopan for the treatment of ANCA-associated vasculitis. N Engl J Med 2021; 384:599609. doi: 10.1056/NEJMoa2023386

  • 5.

    Walsh M, et al.. Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis. N Engl J Med 2020; 382:622631. doi: 10.1056/NEJMoa1803537

  • 6.

    Kronbichler A, et al.. Frequency, risk factors and prophylaxis of infection in ANCA‐associated vasculitis. Eur J Clin Invest 2015; 45:346368. doi: 10.1111/eci.12410

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Flossmann O, et al.. Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70:488494. doi: 10.1136/ard.2010.137778

  • 8.

    Robson J, et al.. Glucocorticoid treatment and damage in the anti-neutrophil cytoplasm antibody-associated vasculitides: Long-term data from the European Vasculitis Study Group trials. Rheumatology (Oxford) 2015; 54:471481. doi: 10.1093/rheumatology/keu366

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    McGregor JAG, et al.. Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7:240247. doi: 10.2215/CJN.05610611

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Goupil R, et al.. Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8:416423. doi: 10.2215/CJN.07300712

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 11.

    Charlier C, et al.. Risk factors for major infections in Wegener granulomatosis: Analysis of 113 patients. Ann Rheum Dis 2009; 68:658663. doi: 10.1136/ard.2008.088302

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Smith RM, et al.. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79:12431249. doi: 10.1136/annrheumdis-2019-216863

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Jayne D, et al.. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 2003; 349:3644. doi: 10.1056/NEJMoa020286

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 14.

    de Groot K, et al.. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 2009; 150:670680. doi: 10.7326/0003-4819-150-10-200905190-00004

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 15.

    Guillevin L, et al.. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 2014; 371:17711780. doi: 10.1056/NEJMoa1404231

  • 16.

    Charles P, et al.. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: Results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2). Ann Rheum Dis 2018; 77:11431149. doi: 10.1136/annrheumdis-2017-212878

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 17.

    Charles P, et al.. Long-term rituximab use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: A randomized trial. Ann Intern Med 2020; 173:179187. doi: 10.7326/M19-3827

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Smith RM, et al.. Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Dis 2020; 79:12431249. doi: 10.1136/annrheumdis-2019-216863

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 19.

    Smith R, et al.. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease. Nephrol Dial Transplant 2020; 35 (Suppl 3):LB004. doi: 10.1093/ndt/gfaa146.LB004

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Smith R, et al.. A randomized, controlled trial of rituximab versus azathioprine after induction of remission with rituximab for patients with ANCA-associated vasculitis and relapsing disease [abstract]. Arthritis Rheumatol 2019; 71 (Suppl 10):806. https://acrabstracts.org/abstract/a-randomized-controlled-trial-of-rituximab-versus-azathioprine-after-induction-of-remission-with-rituximab-for-patients-with-anca-associated-vasculitis-and-relapsing-disease/

    • PubMed
    • Search Google Scholar
    • Export Citation

ANCA-Associated Vasculitis Circa 2020–2021 The March of Advancement Continues

Sam Kant Sam Kant, MD, and Duvuru Geetha, MBBS, MD, are affiliated with the Division of Nephrology, Department of Medicine, Johns Hopkins University of School of Medicine, Baltimore, MD.

Search for other papers by Sam Kant in
Current site
Google Scholar
PubMed
Close
and
Duvuru Geetha Sam Kant, MD, and Duvuru Geetha, MBBS, MD, are affiliated with the Division of Nephrology, Department of Medicine, Johns Hopkins University of School of Medicine, Baltimore, MD.

Search for other papers by Duvuru Geetha in
Current site
Google Scholar
PubMed
Close
Restricted access
Save